Referrals to Vivos’ Las Vegas sleep centers rose about threefold. Added revenue is expected in Q4.

Vivos Therapeutics (VVOS) closed its acquisition of a 50% interest in a pseudohypoxia test and related intellectual property from SOD Sciences. The deal includes issuing 12,000 shares of Series C Convertible Preferred Stock, expected to increase stockholders’ equity by over $10 million. The companies plan to negotiate agreements to market products through new channels, potentially expanding Vivos' market reach to over 325,000 patients.

Vivos Therapeutics, Inc. (VVOS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel Transaction Expected to Add More Than $10 Million to Stockholders’ Equity

Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.

Vivos Therapeutics (VVOS) said it will collaborate with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, LLC, a physician-aligned management services organization to expand integrated diagnosis and treatment for obstructive sleep apnea and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida. The initial focus is Palm Beach County.

Kimberly-Clark (KMB) priced a $4.9B private offering of senior notes in five tranches, with maturities ranging from 2028 to 2036. The proceeds will fund its acquisition of Kenvue, expected in Q4 2026, and general corporate purposes. The notes may be redeemed if the acquisition is not completed by May 31, 2027.

Kimberly-Clark (KMB) priced a $4.9 billion debt offering for its Kenvue acquisition. The notes, due 2028-2036, will fund the deal. The offering is not tied to the acquisition's completion, but notes may be redeemed if the deal falls through. The notes are for institutional buyers and non-U.S. persons.